Gland Pharma Receives USFDA Tentative Approval for Brimonidine Tartrate Eye Solution

Gland Pharma has received tentative approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.025%, an over-the-counter product indicated to relieve eye redness. The drug is bioequivalent and therapeutically equivalent to Bausch + Lomb's Lumify Ophthalmic Solution. Gland Pharma, established in 1978 in Hyderabad, reported a 27.7% rise in net profit and operates globally across 60 countries.